Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Boehringer Ingelheim
McKinsey
Moodys
Colorcon

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Abatacept - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for abatacept

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Juvenile Diabetes Research FoundationEarly Phase 1
Medical College of WisconsinEarly Phase 1
Carla Greenbaum, MDEarly Phase 1

See all abatacept clinical trials

Recent Litigation for abatacept

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28
CELGENE CORPORATION v. SANDOZ INC.2018-06-26

See all abatacept litigation

PTAB Litigation
PetitionerDate
Crescendo Bioscience, Inc2017-04-12

See all abatacept litigation

Pharmacology for abatacept
Ingredient-typeRecombinant Fusion Proteins
Physiological EffectDecreased Cytokine Activity

Patent Text Search: US Patents for abatacept

These patents were identified by searching patent claims

International Patents for abatacept

Supplementary Protection Certificates for abatacept

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
01730049 Spain   Start Trial PRODUCT NAME: SARILUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1196; DATE OF AUTHORISATION: 20170623; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1196; DATE OF FIRST AUTHORISATION IN EEA: 20170623
2015 00021 Denmark   Start Trial PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141023
2017000015 Germany   Start Trial PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945-C(2015)4704 20150703
0728 Netherlands   Start Trial DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN
0170010 00272 Estonia   Start Trial PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014
17C/054 Belgium   Start Trial PRODUCT NAME: KEVZARA - SARILUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
2017000101 Germany   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Express Scripts
AstraZeneca
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.